Replies to BiDil for Heart Failure in Black Patients: Implications of the U.S. Food and Drug Administration Approval — Ann Intern Med

In the Balance: BiDil for Heart Failure in Black Patients: Implications of the U.S. Food and Drug Administration Approval

Kirsten Bibbins-Domingo and
Alicia Fernandez

Ann Intern Med January 2, 2007 146:52-56

Correction
- Kirsten Bibbins-Domingo, PhD, MD
- Alicia Fernandez, MD
University of California, San Francisco
This article incorrectly states that "increased levels of nitric oxide in black people that are associated with adverse heart failure outcomes and may be reduced by hydralazine hydrochloride–isosorbide nitrate therapy." This statement should read that lower levels of available nitric oxide in black people are associated with adverse heart failure outcomes and may be enhanced by hydralazine hydrochloride–isosorbide nitrate therapy.

Conflict of Interest:

None declared

Submit response
Published January 18, 2007

Current Issue

December 1, 2009, 151 (11)